Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg)
RB Machado, P Fabrini, AM Cruz, E Maia… - Contraception, 2004 - Elsevier
This open, prospective, noncomparative study evaluated clinical and metabolic aspects of
the use of a contraceptive combination of ethinyl estradiol (30 μg) and gestodene (75 μg) …
the use of a contraceptive combination of ethinyl estradiol (30 μg) and gestodene (75 μg) …
A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 …
J Endrikat, C Klipping, C Gerlinger, A Ruebig… - Contraception, 2001 - Elsevier
In this double-blind study we compared the influence of two oral contraceptives, a 23-day
regimen with 20 μg ethinyl estradiol and 75 μg gestodene (23-day 20/75) and a 21-day …
regimen with 20 μg ethinyl estradiol and 75 μg gestodene (23-day 20/75) and a 21-day …
Clinical and metabolic effects of a pill containing 30 mcg ethinylestradiol plus 75 mcg gestodene
P Fioretti, F Fruzzetti, R Navalesi, C Ricci, R Miccoli… - Contraception, 1989 - Elsevier
The clinical and metabolic effects of a short-term treatment with a combination contraceptive
pill containing 30 mcg ethinylestradiol and 75 mcg gestodene were evaluated in a group of …
pill containing 30 mcg ethinylestradiol and 75 mcg gestodene were evaluated in a group of …
A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 …
J Endrikat, U Müller, B Düsterberg - Contraception, 1997 - Elsevier
The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …
Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive
U Täuber, W Kuhnz, M Hümpel - American journal of obstetrics and …, 1990 - Elsevier
The pharmacokinetic and protein-binding properties of gestodene and ethinyl estradiol have
been investigated after single and multiple dosing in several studies in 83 healthy, young …
been investigated after single and multiple dosing in several studies in 83 healthy, young …
Metabolic changes during treatment with two different progestogens
H Refn, A Kjær, AM Lebech, B Borggaard… - American journal of …, 1990 - Elsevier
Two triphasic oral contraceptives containing the same amount of ethinyl estradiol in
combination with gestodene or levonorgestrel were compared with respect to contraceptive …
combination with gestodene or levonorgestrel were compared with respect to contraceptive …
Clinical and metabolic effects of a triphasic pill containing gestodene
F Fruzzetti, C Ricci, I Nicoletti, P Fioretti - Contraception, 1992 - Elsevier
The clinical and metabolic effects of a low-dose triphasic oral contraceptive containing
gestodene were investigated in 42 healthy women during 6 months of treatment. No …
gestodene were investigated in 42 healthy women during 6 months of treatment. No …
Clinical acceptability of monophasic gestodene
B Düsterberg, K Brill - American journal of obstetrics and gynecology, 1990 - Elsevier
The monophasic low-dose contraceptive containing 30 μg of ethinyl estradiol and 75 μg of
gestodene has been tested in numerous clinical studies to determine contraceptive …
gestodene has been tested in numerous clinical studies to determine contraceptive …
A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol …
J Endrikat, MA Jaques, M Mayerhofer, C Pelissier… - Contraception, 1995 - Elsevier
The aim of this study was to compare contraceptive reliability, cycle control and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a …
an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a …
A 12-month clinical investigation with a 24-day regimen containing 15 μg ethinylestradiol plus 60 μg gestodene with respect to hemostasis and cycle control
F Fruzzetti, AR Genazzani, C Ricci, F De Negri, C Bersi… - Contraception, 2001 - Elsevier
The effects of a 24-day regimen containing 15 μg ethinyl estradiol (EE) plus 60 μg
gestodene on cycle control and on hemostasis, were evaluated in 58 healthy women (age …
gestodene on cycle control and on hemostasis, were evaluated in 58 healthy women (age …